Company intelligence / Profile preview
Immuthera
Delaware, United Statesimmuthera.bio ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Immuthera is clinically advancing cell therapies for autoimmune and neuroinflammatory diseases using Treg and mRNA platforms. The lead program (PTG-007, autologous Treg therapy for pre-symptomatic type 1 diabetes) is entering FDA IND-enabling studies, with support for a registrational adaptive Phase 2/3 trial. European pediatric regulatory authorities have also issued a positive opinion for this therapy, and early clinical data indicate strong safety and potential for early intervention in disease progression[4][5][6].
- Therapeutic areas
- ImmunologyNeurologyEndocrinology
- Modalities
- Cell therapymRNA-based drugsT cell receptor engineered T cell therapyCAR-T cell therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Antion BiosciencesNoble Capital MarketsKinexum Services
Beyond the preview
Go deeper on Immuthera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immuthera.